© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
MJH Life Sciences
2 Clark Dr
September 30, 2021
Patients with relapsed or refractory chronic lymphocytic leukemia are generally divided by those exposed to Bruton's tyrosine kinase inhibitors (BTKi), patients relapsing after venetoclax, and patients relapsing after BTKi and B-cell lymphoma-2 inhibitors.
September 03, 2021
Alterations in the amino acid profile of children with attention-deficit hyperactivity disorder may support further research into potential new treatment strategies.
August 20, 2021
The agents that have been evaluated and approved, and those that are coming in the pipeline, make for an exciting time to consider directed therapies.
August 13, 2021
New treatments show promise for patients with KRAS G12C–mutated disease.
August 12, 2021
The FDA approved pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced RCC.
August 05, 2021
Erenumab was found to have a sustained efficacy as a monotherapy treatment for episodic migraine that was found to not respond to 2 to 4 prior preventive treatments.